New drug candidates reverse drug resistance in multiple myeloma in preclinical models

31-Oct-2018 - In an article Medical University of South Carolina investigators report that a new compound enhances the efficacy of proteasome inhibitors (PIs), the standard-of-care for the treatment of multiple myeloma (MM), in cell culture and in preclinical models. The efficacy and safety of the novel ...

This tiny particle might change millions of lives

Nanoparticle targets kidney disease for drug delivery

22-Aug-2018 - Remember the scene in the movie Mission: Impossible when Tom Cruise has to sneak into the vault? He had to do all sorts of moves to avoid detection. That's what it's like to sneak a targeted drug into a kidney and keep it from getting eliminated from the body. Since kidneys are the filtering ...

Shooting the achilles heel of nervous system cancers

24-Jul-2017 - Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center devised a strategy to target cancer cells while sparing normal cells. ...

Macrophages engulf cancer cells in solid tumors

21-Jul-2017 - One reason cancer is so difficult to treat is that it avoids detection by the body. Agents of the immune system are constantly checking the surfaces of cells for chemical signals that say they belong, but cancer cells express the same chemical signals as healthy ones. Without a way for the immune ...

Targeting breast cancer metabolism to fight the disease

28-Nov-2016 - How does a cancer cell burn calories? New research from Thomas Jefferson University shows that breast cancer cells rely on a different process for turning fuel into energy than normal cells. "Our finding is part of a growing interest in studying the metabolic function of cancer," says Ubaldo ...

‘Cellbots’ chase down cancer, deliver drugs directly to tumors

04-Oct-2016 - UC San Francisco scientists have engineered human immune cells that can precisely locate diseased cells anywhere in the body and execute a wide range of customizable responses, including the delivery of drugs or other therapeutic payloads directly to tumors or other unhealthy tissues. In ...

H3 Biomedicine and Selvita Reach First Research Milestone in Precision Cancer Medicines Collaboration

Companies Advance Multiple Co-discovery Programs for First-in-class Targets in Oncology

27-May-2014 - H3 Biomedicine Inc. and Selvita announced that they have achieved the first research milestone in their strategic collaboration to develop breakthrough precision medicines for cancers. The companies have validated the importance and druggability of a kinase target in a specific genetic context ...

Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease

23-Nov-2010 - Abbott announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease). Study results suggest ...

Epratuzumab phase IIb data show pipeline drug had positive effect in patients suffering from systemic lupus erythematosus

11-Nov-2010 - UCB and U.S. based partner Immunomedics Inc.announced that results from the phase IIB study, EMBLEM™, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE. The ...

Generex Oncology Granted United States Patent for AE37 Peptide Vaccine

14-Jul-2010 - Generex Biotechnology Corporation announced that its wholly-owned subsidiary, Antigen Express, Inc., has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the ...